Australia’s Therapeutic Goods Administration (TGA) has told consumers not to use Synedica peptide products. Its 5 November 2026 alert follows laboratory findings that several products did not match their labels, including a product sold as retatrutide.
What did the laboratory find?
The TGA’s safety advisory identifies four products:
- Synedica BPC 157 & TB 500 10 mg: no TB-500 detected.
- Synedica KLOW 80 mg: no TB-500 detected.
- Synedica BARBIE KLOW 100 mg: no TB-500 detected.
- Synedica Retatrutide 10 mg: less retatrutide than labelled, with substantial variation between samples.
The notice does not give the number of samples tested, the measured retatrutide amounts or a count of associated injuries. These findings cannot establish the contents of every vial or the chance of harm to an individual.
What should someone with these products do?
The TGA advises stopping Synedica products, taking remaining supplies to a local pharmacy for safe disposal, discussing health concerns with a health professional and reporting suspected side effects. Its warning concerns unapproved products; it is not an instruction to stop prescribed diabetes treatment.
Retatrutide research is not permission to buy online vials
The US Food and Drug Administration’s current advice says retatrutide is not an ingredient in an FDA-approved medicine, has not been established as safe and effective for any condition, and cannot legally be used in compounding under US federal law.
A clinical trial and a product sold directly online are different things. Our retatrutide evidence guide explains that distinction. A research headline is not a prescription, and a seller’s use of the same drug name does not establish equivalent ingredients, manufacturing or safety.
The FDA also warns against unapproved products offered to consumers under labels such as “for research purposes”. It advises obtaining prescriptions from a doctor and using a state-licensed pharmacy in the US. It identifies warning signs including no required prescription, no available licensed doctor, damaged or misleading packaging, and claims that an unapproved compounded product is the same as an approved medicine.
Those are US regulatory and purchasing safeguards, not a claim that every country has identical prescribing rules. Nor does a familiar medicine name make an unfamiliar online seller safe.
When symptoms need emergency help
A serious allergic reaction can progress quickly. The NHS anaphylaxis guidance says to call 999 in the UK for sudden swelling of the lips, mouth, tongue or throat, struggling to breathe, a tight throat or difficulty swallowing, or sudden severe confusion, dizziness or collapse. Outside the UK, use your local emergency number.
If you have an adrenaline auto-injector and suspect anaphylaxis, use it according to its instructions and call an ambulance. Lie down; if breathing is difficult, raise your shoulders or sit up slowly. Do not stand or walk, even if you feel better. If symptoms have not improved after five minutes, use a second auto-injector if available. Emergency care is still needed after using one.
These are general emergency instructions, not evidence that the tested products caused a particular allergic reaction. Do not wait for an online reply or a product report before seeking emergency help.
Questions to take to your pharmacist or diabetes team
- I have used a product bought outside my usual pharmacy. What details should I bring so you can assess it?
- Could any symptoms or other medicines change what help I need now?
- What approved treatment options fit my health needs and local availability?
For broader background, see our type 2 diabetes guide. This article provides public safety information, not an individual diagnosis or instructions for changing medicine doses.